{
    "root": "34653b37-89cb-0f5f-e063-6394a90ab65f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Olanzapine",
    "value": "20250505",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (110000 WAMW)",
            "code": "5Y0974F5PW"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "OLANZAPINE",
            "code": "N7U69T4SZR"
        }
    ],
    "indications": "olanzapine atypical antipsychotic indicated : oral formulation : • treatment schizophrenia . ( 1.1 ) adults : efficacy established three trials patients schizophrenia : two 6-week trials one maintenance trial . ( 14.1 ) adolescents ( ages 13 17 ) : efficacy established one 6week trial patients schizophrenia ( 14.1 ) . increased potential ( adolescents compared adults ) weight gain dyslipidemia may lead clinicians consider prescribing drugs first adolescents . ( 1.1 ) • acute treatment manic mixed episodes associated bipolar disorder maintenance treatment bipolar disorder . ( 1.2 ) adults : efficacy established three trials patients manic mixed episodes bipolar disorder : two 3- 4-week trials one maintenance trial . ( 14.2 ) adolescents ( ages 13 17 ) : efficacy established one 3-week trial patients manic mixed episodes associated bipolar disorder ( 14.2 ) . increased potential ( adolescents compared adults ) weight gain dyslipidemia may lead clinicians consider prescribing drugs first adolescents . ( 1.2 ) medication therapy pediatric patients schizophrenia bipolar disorder undertaken thorough diagnostic evaluation careful consideration potential risks . ( 1.3 ) adjunct valproate lithium treatment manic mixed episodes associated bipolar disorder . ( 1.2 ) efficacy established two 6-week trials adults ( 14.2 ) . maintenance efficacy systematically evaluated . olanzapine fluoxetine combination : treatment depressive episodes associated bipolar disorder . ( 1.5 ) efficacy established symbyax ( olanzapine fluoxetine combination ) ; refer product label symbyax . treatment treatment resistant depression . ( 1.6 ) efficacy established symbyax ( olanzapine fluoxetine combination ) adults ; refer product label symbyax .",
    "contraindications": "schizophrenia adults ( 2.1 ) oral : start 5 10 mg daily ; target : 10 mg/day within several days schizophrenia adolescents ( 2.1 ) oral : start 2.5 5 mg daily ; target : 10 mg/day bipolar disorder ( manic mixed episodes ) adults ( 2.2 ) oral : start 10 15 mg daily bipolar disorder ( manic mixed episodes ) adolescents ( 2.2 ) oral : start 2.5 5 mg daily ; target : 10 mg/day bipolar disorder ( manic mixed episodes ) lithium valproate adults ( 2.2 ) oral : start 10 mg daily depressive episodes associated bipolar disorder adults ( 2.5 ) oral combination fluoxetine : start 5 mg oral olanzapine 20 mg fluoxetine daily depressive episodes associated bipolar disorder children adolescents ( 2.5 ) oral combination fluoxetine : start 2.5 mg oral olanzapine 20 mg fluoxetine daily treatment resistant depression adults ( 2.6 ) oral combination fluoxetine : start 5 mg oral olanzapine 20 mg fluoxetine daily lower starting dose recommended debilitated pharmacodynamically sensitive patients patients predisposition hypotensive , potential slowed metabolism . ( 2.1 ) . olanzapine may given without regard meals ( 2.1 ) . olanzapine fluoxetine combination : adjustments , indicated , made individual components according efficacy tolerability . ( 2.5 , 2.6 ) olanzapine monotherapy indicated treatment depressive episodes associated bipolar disorder treatment resistant depression . ( 2.5 , 2.6 ) safety co-administration doses 18 mg olanzapine 75 mg fluoxetine evaluated adults . ( 2.5 , 2.6 ) safety co-administration doses 12 mg olanzapine 50 mg fluoxetine evaluated children adolescents ages 10 17 . ( 2.5 )",
    "warningsAndPrecautions": "olanzapine tablets usp , 7.5 mg white , film coated , oval , biconvex tablets debossed “ r ” 7.5 one side “ 0165 ” side supplied ndc : 70518-1611-00 ndc : 70518-1611-01 ndc : 70518-1611-02 packaging : 30 1 blister pack packaging : 30 1 bottle plastic packaging : 30 1 blister pack store olanzapine tablets controlled room temperature , 20° 25°c ( 68° 77°f ) [ usp ] . usp defines controlled room temperature temperature maintained thermostatically encompasses usual customary working environment 20° 25°c ( 68° 77°f ) ; results mean kinetic temperature calculated 25°c ; allows excursions 15° 30°c ( 59° 86°f ) experienced pharmacies , hospitals , warehouses . protect olanzapine tablets light moisture . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "none olanzapine monotherapy . using olanzapine fluoxetine combination , also refer section package insert symbyax . information lithium valproate , refer section package inserts products .",
    "indications_original": "Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: • Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13 to 17): Efficacy was established in one 6week trial in patients with schizophrenia (14.1) . The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.1) • Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13 to 17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder (14.2) . The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. (1.2) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. (1.3) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As Olanzapine and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder.( 1.5 ) Efficacy was established with Symbyax (olanzapine and fluoxetine in combination); refer to the product label for Symbyax. Treatment of treatment resistant depression. (1.6) Efficacy was established with Symbyax (olanzapine and fluoxetine in combination) in adults; refer to the product label for Symbyax.",
    "contraindications_original": "Schizophrenia in adults (2.1) Oral: Start at 5 to 10 mg once daily;Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) Oral: Start at 2.5 to 5 mg once daily;Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) in adults (2.2) Oral: Start at 10 or 15 mg once daily Bipolar I Disorder (manic or mixed episodes) in adolescents (2.2) Oral: Start at 2.5 to 5 mg once daily;Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) with lithium or valproate in adults (2.2) Oral: Start at 10 mg once daily Depressive Episodes associated with Bipolar I Disorder in adults ( 2.5) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily Depressive Episodes associated with Bipolar I Disorder in children and adolescents (2.5) Oral in combination with fluoxetine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily Treatment Resistant Depression in adults (2.6) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily Lower starting dose recommended in debilitated or pharmacodynamically sensitive patients or patients with predisposition to hypotensive reactions, or with potential for slowed metabolism. ( 2.1 ). Olanzapine may be given without regard to meals ( 2.1 ). Olanzapine and Fluoxetine in Combination: Dosage adjustments, if indicated, should be made with the individual components according to efficacy and tolerability. ( 2.5 , 2.6 ) Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder or treatment resistant depression. ( 2.5 , 2.6 ) Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 , 2.6 ) Safety of co-administration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17. ( 2.5)",
    "warningsAndPrecautions_original": "Olanzapine Tablets USP, 7.5 mg are white, film coated, oval, biconvex tablets debossed “R” on\n                  7.5\n                  one side and “0165” on other side and are supplied in\n                  \n                  NDC: 70518-1611-00\n                  NDC: 70518-1611-01\n                  NDC: 70518-1611-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store olanzapine tablets at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses.\n                  Protect olanzapine tablets from light and moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "None with olanzapine monotherapy.\n                     When using olanzapine and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax.\n                     For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products."
}